Alnylam pharmaceuticals reports q3 results

Alnylam pharmaceuticals reports third quarter 2019 financial results and highlights recent period activity.q3 non-gaap loss per share $1.50.q3 gaap loss per share $1.92.q3 earnings per share estimate $-2.04 -- refinitiv ibes data.qtrly total revenues $70.1 million versus $2.1 million.expects its current cash, cash equivalents, and marketable debt securities will support company operations for multiple years.alnylam pharmaceuticals - reiterates expectations for 2019 non-gaap research and development expenses to be in range of $550 to $575 million.alnylam pharmaceuticals - reiterates expectations for 201 non-gaap sg&a expenses to be in range of $390 to $400 million.q3 revenue view $56.4 million -- refinitiv ibes data.
ALNY Ratings Summary
ALNY Quant Ranking